|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A sensitive, specific, and fast ultra-high performance liquid chromatography/tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for determination of caffeine (probe of CYP1A2), tolbutamide (probe of CYP2C9), dextromethorphan (probe of CYP2D6), and alprazolam (probe of CYP3A4/5) in human serum.
|
31744669 |
2020 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYP1A2 activity was assessed 2 hours after the ingestion of a drink containing caffeine through measurement of the metabolic ratio of paraxanthine (17X) over caffeine (137X) by LC-MS/MS or LC-UV.
|
31608602 |
2020 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Spot urine samples obtained 6 hours following 200-mg caffeine administration were used to determine caffeine metabolite ratios (CMRs); blood samples were used to determine CYP1A2*1F (rs762551) and CYP1A2*1C (rs2069514) polymorphisms and the hormonal profile (estradiol, progesterone, and luteinizing and follicle-stimulating hormones) at EFP, LFP, and LP.
|
30591530 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Some common genes that are included in nutrition-based multigene test panels include CYP1A2 (rate of caffeine break down), MTHFR (folate usage), NOS3 (risk of elevated triglyceride levels related to omega-3 fat intake), and ACE (blood pressure response in related to sodium intake).
|
31254340 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The effect of CYP1A2 genotype on the ergogenic properties of caffeine during resistance exercise: a randomized, double-blind, placebo-controlled, crossover study.
|
29532291 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cooking decreases the activity of FBW in inhibition of CYP1A2 mediating CF metabolism.
|
31353578 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A previous clinical study of obeticholic acid (OCA) with caffeine suggested that OCA may be a useful positive control to establish a method to evaluate CYP1A2 downregulation and to investigate the mechanism of its downregulation.
|
31472121 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We used BLUES to investigate binding modes of caffeine in the active site of its metabolizing enzyme Cytochrome P450 1A2 with the aim of elucidating metabolite-formation profiles at different concentrations.
|
31132250 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study aimed to examine whether functional single nucleotide polymorphisms (SNPs) in 1976T > C (ADORA2A; rs5751876) and -163C > A (CYP1A2; rs762551) influence the effect of caffeine on the postprandial glucose (GLU) response to a carbohydrate meal.
|
31324842 |
2019 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For instance, oral caffeine is used to quantify hepatic CYP1A2 activity, and oral dagibatran etexilate for intestinal P-glycoprotein (P-gp) activity.
|
30156973 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the use of a stratified value of CYP1A2 content derived from a Han Chinese cohort with a small sample size instead of the pooled value of all Chinese cohorts involved regardless of Chinese sub-ethnicity resulted in inadequate prediction of CYP1A2-mediated pharmacokinetics in terms of caffeine and theophylline in either young or elderly Chinese subjects.
|
30767128 |
2019 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Caffeine increased exposure during pregnancy was related to reduced activity of caffeine metabolizing enzyme CYP1A2.
|
30689395 |
2019 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Enzyme phenotyping was assessed in saliva and urine using caffeine metabolite ratios as follows: CYP1A2: 17X/137Χ (saliva) and CYP1A2: (AFMU+1U+1X)/17U, CYP2A6: 17U/(17U + 17X), XO: 1U/(1U+1X) and NAT2: AFMU/(AFMU+1U+1X) (urine).
|
31082462 |
2019 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The trial variance for 22 h EE was not significantly related to the variance in plasma caffeine levels or CYP1A2*1F allele carriers and non-carriers.
|
31694152 |
2019 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all cases, CYP1A2 activity was decreased with an increasing inhibitor concentration, confirming the inhibition of caffeine metabolism in vivo.
|
31519293 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In stratified analysis, a statistical significance within the caffeinated group was observed for the change in systolic BP in the stratum of CYP1A2 polymorphism with daily caffeine consumption ≤90 mg/day: change in systolic BP in the CYP1A2 rs762551 CC group (mean ± SD = 11.8 ± 5.9) was higher than that in the AA/CA group (4.1 ± 5.5).
|
30773300 |
2019 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The effects of caffeine on basketball performance were established according to players' CYP1A2 genotype (rs762551): AA homozygotes (n = 10) and C-allele carriers (n = 9).
|
29668752 |
2018 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Enzyme phenotyping was assessed in saliva and urine using caffeine and paracetamol metabolite ratios as follows: CYP1A2: 17X/137X (saliva) and (AFMU+1U+1X)/17U, CYP2A6: 17U/(17U + 17X), XO: 1U/(1U+1X), NAT2: AFMU/(AFMU+1U+1X) and UGT1A1/1A6: glucuronidated/total paracetamol (urine).
|
30266316 |
2018 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we briefly review the drivers of this inter-individual variation in caffeine response, focusing on the impact of common polymorphisms within two genes, CYP1A2 and ADORA2A.
|
28853006 |
2018 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of tivantinib doses on the pharmacokinetics of the probe drugs for CYP1A2 (caffeine), CYP2C9 (S-warfarin), CYP2C19 (omeprazole), and CYP3A4 (midazolam), and for P-glycoprotein (digoxin) was investigated in 28 patients with advanced cancer using a cocktail probe approach.
|
28865153 |
2018 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Specifically, the rs762551 SNP in the CYP1A2 gene has been demonstrated to influence caffeine metabolism, with carriers of the C allele considered to be of a 'slow' metaboliser phenotype.
|
29569539 |
2018 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The probes for testing CYP1A2 are phenacetin and caffeine while for CYP2C9 tolbutamide.
|
28992765 |
2018 |
|
Caffeine related disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlations were not seen between PhIP-Alb adduct levels and PhIP intake levels (P = 0.76), the amount of PhIP accrued in hair (P = 0.13), the amounts of N-oxidized urinary metabolites of PhIP (P = 0.66) or caffeine CYP1A2 activity (P = 0.55), a key enzyme involved in the bioactivation of PhIP.
|
30247550 |
2018 |
|
Caffeine related disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The pharmacokinetics of caffeine are highly variable among individuals due to a polymorphism at the level of the CYP1A2 isoform of cytochrome P450, which metabolizes 95% of the caffeine ingested.
|
29514871 |
2018 |
|
Caffeine related disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Activity of five isozymes was estimated by comparing plasma pharmacokinetics of substrates and their metabolites (caffeine/paraxanthine for CYP1A2, losartan/E-3174 for CYP2C11, omeprazole/5-hydroxyl omeprazole for CYP2C6, dextromethorphan/dextrophan for CYP2D2 and midazolam/1-hydroxyl midazolam for CYP3A1/2) between control and drug treatment groups.
|
29425645 |
2018 |